Mindtrix Secures RMB 150 Million in Series Angel Funding to Advance Visual Cortical Prosthesis for the Blind
Mindtrix
Invasive Brain-Computer Interface Technology Developer
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Volume Increase in Centralized Procurement | Ophthalmic Optometry Column
Mindtrix Technology Co., Ltd.(Abbreviation: "Mindtrix"") announced,Has successfully completed a series of angel-round financings, including angel+, and angel++ rounds.Total financing amount reached 150 million yuanThe investors include CAS Star, Leading Capital, Haibei Venture Capital, Huafang Capital, Delian Capital, Hony Capital, Hengxu Capital, Dingsheng Quantum, and Banfei Incubation.
Mindtrix stated that the funds from this financing will be mainly used forAdvance Visual Reconstruction Brain-Computer Interface Technology Towards Clinically Validated Product Stage, laying a technical and data foundation for the registration clinical trial. This is one of the largest early-stage financings publicly disclosed in the field of brain-computer interface for visual reconstruction in China.
# Visual Reconstruction Niche Track
Mindtrix SelectionVisual ReconstructionAs the main direction, forming a differentiation from the majority of brain-computer interface companies.
Visual Reconstruction Brain-Computer Interface restores visual function for completely blind patients with total optic nerve damage, who cannot be cured by traditional medicine, through implantable technology. The technical approach is divided intoRetinal Implant and Visual Cortex ImplantTwo categories:
The former is suitable for patients with retinopathy but intact optic nerves, represented by Science Corporation (Prima system);
The latter is suitable for patients with optic nerve damage or eyeball loss, and representative companies include Neuralink (Blindsight device) and Mindtrix.
Mindtrix adoptsVisual Cortex Implant RouteIn September 2025, the company completed the world's first functional interaction verification for visual reconstruction with "complex patterns + multiple colors." In February 2026, it completed China's first quantitative encoding reconstruction of grayscale information. In March 2026, its technology was selected as a significant achievement in assistive technology by the China Disabled Persons' Federation.
Globally,Visual Reconstruction Brain-Computer Interface Has Completed the Mechanism Validation Phase, currently in the engineering breakthrough and clinical transformation stage. Science Corporation's Prima system has submitted a CE certification application to the EU, with clinical trial results of 38 patients published in The New England Journal of Medicine; Neuralink's Blindsight device has received the FDA "Breakthrough Device" designation, with plans to initiate human trials in 2026.
# From Feasibility Validation to Registration Trials
In addition to Mindtrix, other Chinese manufacturers have also achieved a concentrated outbreak of clinical breakthroughs:
Step Care: In February 2025, completed a B-round financing of 350 million yuan, setting a record for the largest single financing in China's implantable brain-computer interface industry; in March 2026, completed a strategic financing of 500 million yuan led by Alibaba, with SDIC Innovation following up, and existing shareholders such as Tencent continuing to invest.Total financing in the past year exceeds 1.1 billion yuanMindtrix Technology Co., Ltd. completed the first prospective clinical trial of an invasive brain-computer interface in China in 2025, finished the first clinical implantation of a 256-channel invasive brain-computer interface in China in early 2026, and plans to launch a large-scale multi-center registration clinical trial by mid-2026, aiming to enroll approximately 40 patients within the year.
BrainRobotics: In March 2026, its self-developed implantable brain-computer interface hand motion compensation system (NEO) officially received the NMPA Class III medical device registration certificate, becomingThe World's First Approved and Marketed Implantable Brain-Computer Interface Medical DeviceThe product adopts a minimally invasive epidural implantation solution and has completed 36 clinical surgeries. Mindtrix Technology Co., Ltd. registered for IPO coaching at the Shanghai Securities Regulatory Bureau in February 2026, striving for the Sci-Tech Innovation Board.
NeuroTiger Technology:The first invasive clinical trial was completed in December 2025 at Huashan Hospital Affiliated with Fudan University, and by the end of 2025, 54 human implants had been completed.Plan to Expand Clinical Research Centers to 10 by 2026。
Warm Core Jia: Complete the type inspection of the high-resolution visual brain-computer interface medical device in the second half of 2024, and finish by March 2025.First Functional Animal Experiment Validation on Cynomolgus Monkeys in China。
# From Inclusion in Medical Insurance to Future Industry Planning
Policy-level support provides institutional guarantees for the clinical transformation and industrialization of visual reconstruction brain-computer interfaces.
In March 2025, the National Healthcare Security Administration introduced"Guidelines for the Establishment of Medical Service Price Items for Nervous System Services (Trial)"，Brain-Computer Interface Enters Medical Insurance Billing System for the First Time, Initial Commercial Closed Loop FormedIn July, the Ministry of Industry and Information Technology, the National Development and Reform Commission, and five other departments jointly issued the "Implementation Opinions on Promoting the Innovative Development of the Brain-Computer Interface Industry."Brain-Computer Interface Industry Officially Elevated to National Strategic HeightIn November, the "Fifteenth Five-Year Plan" included brain-computer interface as one of the six future industry directions, indicating that it will be strongly promoted to become a new economic growth point.
At the local level, Shanghai has proposed a specific goal of promoting more than five invasive and semi-invasive brain-computer interface products to complete clinical trials before 2027. Jiangsu Province's first brain-computer interface clinic officially opened in November 2025 at the General Hospital of the Eastern Theater Command, and pilot clinics have also been established in tertiary hospitals in Shanghai and other places.
At the regulatory level, in November 2025, Mindtrix's "Implantable Wireless Brain-Computer Interface System" entered the NMPA's Innovative Medical Device Special Review Process, becoming the first invasive brain-computer interface product in China to enter this "green channel." The NEO product from Boyikang has been approved for an NMPA Class III Innovative Medical Device Registration Certificate.
# Company Profile
Mindtrix was founded in 2024. It is a China-based implantable brain-computer interface enterprise specializing in the field of vision restoration, and also the first innovative platform for vision restoration brain-computer interfaces in China to complete human validation. The company is committed to rebuilding usable visual functions for completely blind patients with total optic nerve damage, who cannot be cured by traditional medicine, through invasive brain-computer interface technology.
Ophthalmology Solutions Case
